Faria Khan, MD
Allergy & Immunology · Gainesville, GANPI 1548212087
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.2% of the total across 326 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 17.0% — the pattern of someone who eats at a lot of different presentations.
Across 326 payments — averaging $22.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$1K
- AstraZeneca$1K
- GSK$700
- Regeneron Healthcare Solutions, Inc.$606
- Teva Pharmaceuticals USA, Inc.$464
- Takeda Pharmaceuticals U.S.A., Inc.$429
- plus $3K from 25 others
What the payments were for
- Food & beverage$7,04397%
- Education$2033%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 38 | $1,229 |
| AstraZeneca | 51 | $1,023 |
| GSK | 42 | $700 |
| Regeneron Healthcare Solutions, Inc. | 22 | $606 |
| Teva Pharmaceuticals USA, Inc. | 29 | $464 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $429 |
| Novartis | 20 | $386 |
| CSL Behring | 11 | $324 |
| Amgen | 14 | $286 |
| Optinose US, Inc. | 15 | $273 |
| Pfizer | 11 | $237 |
| Grifols USA, LLC | 8 | $168 |
| ARS Pharmaceuticals Operations, Inc. | 8 | $143 |
| Biocryst US Sales Co., LLC | 5 | $136 |
| Alk-abello, Inc | 6 | $117 |
| Boehringer Ingelheim | 5 | $101 |
| Pharming Healthcare, Inc. | 3 | $84 |
| Sanofi-aventis U.S. LLC | 1 | $80 |
| Octapharma USA, Inc. | 1 | $77 |
| Covis Pharma GmbH | 4 | $67 |
| Incyte Corporation | 2 | $46 |
| Kaleo, Inc. | 3 | $45 |
| AbbVie | 2 | $43 |
| Intersect ENT, Inc. | 2 | $40 |
| Aimmune Therapeutics, Inc. | 1 | $26 |
| ADMA Biomanufacturing LLC | 1 | $26 |
| Shire North American Group Inc | 1 | $20 |
| Merck | 1 | $20 |
| Blueprint Medicines Corporation | 1 | $19 |
| Mylan Specialty L.p. | 1 | $16 |
| Eyevance Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$114
How this compares
$7,246 in reported general payments places this provider in the 60th percentile of 107 allergy & immunology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 13 | $35,020 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $11,154 |
| Arnuity ElliptaFluticasone Furoate | 31 | $9,406 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $8,715 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $6,009 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $4,179 |
| Azelastine Hcl | 103 | $2,447 |
| Wixela InhubFluticasone Propion/Salmeterol | 12 | $2,209 |
| Zafirlukast | 12 | $1,017 |
| Montelukast Sodium | 60 | $636 |
| Fluticasone Propionate | 45 | $626 |
| Olopatadine Hcl | 11 | $582 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 20 | $507 |
| Ipratropium Bromide | 13 | $407 |
| Levocetirizine Dihydrochloride | 14 | $260 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Arnuity Ellipta, Breo Ellipta, Incruse Ellipta | $700 | $30,74874 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 107 allergy & immunology providers in Georgia.
Other allergy & immunology in Gainesville
- Ronald BeebeGainesville$56K
- Kimberley ShanksGainesville$11K
- William NishGainesville$8K
- Amy BoydGainesville$8K
- Michael MaloneyGainesville$7K
- Michael BlaissRoswell$1.1M
- Deborah BirxAtlanta$470K
- Tracy BridgesAlbany$364K
- Jack EadesMacon$237K
- Stanley FinemanMarietta$186K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.